BYD
27.2.2024 16:21:34 CET | Business Wire | Press release
At the Geneva Motor Show on February 26, the World Car Awards announced the top three finalists for 2024. BYD's models, the BYD SEAL and the BYD DOLPHIN, excelled among a host of competitors, securing spots in the top three for the "World Car of the Year" and "World Urban Car" categories, respectively, and progressing to the final round of the competition. BYD makes history as the first and only Chinese carmaker to be shortlisted in the top three for the "World Car of the Year" category.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20240227393340/en/
BYD SEAL shortlisted in the Top 3 for the "World Car of the Year" category (Photo: Business Wire)
Regarded as the top three automotive accolades globally, the "World Car Awards," "European Car of the Year," and "North American Car of the Year" are highly esteemed. Dubbed the "Oscars of the automotive world", the "World Car Awards" is particularly celebrated for its emphasis on international models, positioning it as a highly anticipated event within the global automotive industry. BYD's exceptional performance highlights its status as a global leader in the New Energy Vehicle space.
These two models, with their distinctive design, cutting-edge technology, and robust safety features, captured the interest of over 100 automotive media experts from 29 countries. In 2023, the BYD SEAL and BYD DOLPHIN achieved five-star ratings in Euro NCAP and ANCAP tests. Notably, BYD SEAL was also nominated for the final European Car of the Year 2024.
As a frontrunner in the new energy vehicle sector, BYD achieved a milestone with over 3 million new energy vehicle sales in 2023, securing the top spot in global sales, for the second year in a row and breaking into the top ten global automotive brands — a first for a Chinese automaker.
So far, BYD's new energy vehicles have a substantial presence across over 70 countries and regions on six continents, encompassing more than 400 cities. In 2023, BYD emerged as a frontrunner in new energy vehicle sales across various international markets, including Thailand, Singapore, Colombia, and Brazil, garnering extensive consumer acclaim and preference.
Aligning with the World Car Awards' mission to foster continual innovation in the automotive sector, BYD is committed to building a comprehensive zero-emission new energy solution through technological innovations. It aims to enhance consumer travel experiences, spearhead the new energy vehicle industry's growth, and actively contribute to the automotive industry's transformation and progress. Looking ahead, BYD will steadfastly pursue its vision to "Cool the Earth by 1°C," continually driving the industry's green and low-carbon transformation and global sustainable development.
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20240227393340/en/
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
OpenRouter Raises $113 Million CapitalG-led Series B as Weekly Volume Explodes to 25T Tokens26.5.2026 15:15:00 CEST | Press release
NVentures, ServiceNow Ventures, MongoDB Ventures, Snowflake Ventures, Databricks Ventures join CapitalG, a16z, Menlo Ventures, and others in backing the high-growth AI infrastructure startup OpenRouter, the AI model exchange, today announced a $113 million Series B led by Alphabet’s independent growth fund, CapitalG, with participation from investors including NVentures (NVIDIA’s venture capital arm), ServiceNow Ventures, MongoDB Ventures, Snowflake Ventures, Databricks Ventures, alongside existing investors including Andreessen Horowitz and Menlo Ventures. OpenRouter’s volume has surged to 25 trillion tokens per week (100 trillion tokens per month), representing a 5X increase from the 5 trillion tokens processed per week just six months ago. The explosion in token demand illustrates how quickly enterprises are deploying agents and scaling AI across multiple models and providers. OpenRouter’s infrastructure manages and optimizes inference and provides access to 400+ models across leadi
Xsolla Expands Its Community Management Tools for Creators, Community Leaders, and Resellers26.5.2026 15:00:00 CEST | Press release
Xsolla Adds New Features For Creators, Community Leader Experience, And Distinct Channels For Emerging Markets Xsolla, a leading global video game commerce company, today announced three simultaneous expansions of its community management tools and products. As the creator economy continues to reshape how games are discovered and the industry accelerates its shift toward direct-to-consumer commerce, Xsolla is building on its community management tools for creators, community leaders, and emerging markets, and will showcase them at TwitchCon Rotterdam later this month. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260526596720/en/ Graphic: Xsolla The games industry has never had a shortage of people who drive player acquisition, loyalty, and commerce; it's had a shortage of infrastructure that recognizes them. Creators stream it. Community leaders build a culture around it. Local resellers get it into the hands of players in
Biocytogen Launches AI-Powered RenSuper™ Platform and Industry-First Fully Automated Antibody Discovery Infrastructure26.5.2026 14:00:00 CEST | Press release
Biocytogen today announced the launch of RenSuper Workstation, a next-generation AI-powered antibody discovery platform providing off-the-shelf access to a large-scale, experimentally validated library of fully human therapeutic antibody sequences, together with the RenSuper High-Throughput Antibody Manufacturing Automation Center, a fully automated infrastructure designed to accelerate antibody validation and production. Built on Biocytogen’s proprietary RenMice® platforms, RenSuper establishes a closed-loop antibody discovery engine combining in vivo immune repertoires, AI-driven candidate selection, automated experimental validation, and scalable manufacturing infrastructure. The platform supports the discovery and development of monoclonal antibodies, bispecifics, multispecifics, antibody-drug conjugates (ADCs), VHHs, and other advanced therapeutic modalities, significantly reducing the time and risk associated with antibody discovery. RenSuper Workstation: AI-Powered One-Click Tar
ViaLase Announces Global Commercial Introduction of the FLIGHT Procedure26.5.2026 14:00:00 CEST | Press release
First commercial femtosecond laser image-guided, high precision trabeculotomy (FLIGHT) treatments mark a new era in interventional glaucoma; one where precision, safety, and the patient experience define the new standard of care ViaLase, Inc., a commercial stage medical technology company pioneering incision-free, laser-based solutions for glaucoma, today announced the successful completion of the first commercial FLIGHT procedures performed at Centre for Sight in London by Sheraz Daya, MD, and Gus Gazzard, MD, and at Breyer, Kaymak & Klabe Augenchirurgie in Düsseldorf, Germany, by Karsten Klabe, MD. The first commercial FLIGHT procedures were performed using the ViaLuxe® Laser System to deliver an incision-free, image-guided femtosecond laser treatment designed to create precise channels through the trabecular meshwork to restore aqueous outflow and reduce intraocular pressure in patients with open-angle glaucoma. “Centre for Sight has always been committed to bringing meaningful inno
BioIVT to Spotlight ADME-Tox Expertise and Solutions at Summer 2026 Events26.5.2026 14:00:00 CEST | Press release
Company will demonstrate how high-quality, well-characterized biospecimens are critical to the success of both new approach methodologies (NAMs) and traditional studies BioIVT, the leading biospecimen solutions provider and global research partner for drug and diagnostic development, today announced it will showcase its broad portfolio of ADME-Tox solutions and research expertise at several leading industry events, including the 2026 MPS World Summit and the ISSX 16th European Meeting. The MPS World Summit takes place May 26-May 29, 2026, in Washington, D.C. BioIVT colleagues will be available at booth #115 to discuss research questions and needs, including preparation, handling, and utilization of the high-quality tissues and cells needed for microphysiological systems (MPS), as well as conducting ADME studies and bioanalysis. BioIVT offers an extensive range of control and disease state biospecimens, including SPHEROID CERTIFIED™ Hepatocytes as well as advanced HEPATOPAC® co-cultures
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom